Onartuzumab
Humanized (from mouse) | |
|---|---|
| Target | scatter factor receptor kinase |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C4422H6820N1168O1363S31 |
| Molar mass | 99147.88 g·mol−1 |
  (what is this?) (verify) | |
Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer.[1][2][3]
Onartuzumab was developed by Genentech, Inc. It is undergoing clinical trials.[4][5][6][7]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab" (PDF). American Medical Association.
- PMID 25806189.
- PMID 25818471.
- S2CID 206059437.
- PMID 23063071.
- PMID 24101053.
- S2CID 20118425.